Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 1
Submit an article Journal homepage
714
Views
5
CrossRef citations to date
0
Altmetric
Articles

Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events

Wayne Gullivera Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Canada;b Newlab Clinical Research Inc, St. John’s, CanadaCorrespondence[email protected]
View further author information
,
Michelle Penneyb Newlab Clinical Research Inc, St. John’s, CanadaView further author information
,
Rebecca Powera Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Canada;b Newlab Clinical Research Inc, St. John’s, CanadaView further author information
,
Susanne Gulliverb Newlab Clinical Research Inc, St. John’s, CanadaView further author information
,
Sonia Montmayeurc Eli Lilly and Company, Indianapolis, IN, USAView further author information
&
Russel Burgec Eli Lilly and Company, Indianapolis, IN, USA;d Division of Pharmaceutical Sciences, Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USAView further author information
Pages 354-360 | Received 30 Mar 2020, Accepted 06 Apr 2020, Published online: 22 Apr 2020

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, Carlo Giovanni Carrera, Paolo Dapavo, Anna Balato, Piergiorgio Malagoli, Stella Mazzoccoli, Aurora Parodi, Silvia Sabatino, Carlotta Buzzoni, Chu-Han Huang & Alessandra Narcisi. (2023) Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study). Journal of Dermatological Treatment 34:1.
Read now
Adam Reich, Catherine Reed, Christopher Schuster, Camille Robert, Tamas Treuer & Ennio Lubrano. (2023) Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021. Journal of Dermatological Treatment 34:1.
Read now
Pim Sermsaksasithorn, Chanidapa Wongtada, Varin Chaaim, Yuda Chongpison & Pravit Asawanonda. (2022) On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study. Journal of Dermatological Treatment 33:7, pages 2963-2974.
Read now

Articles from other publishers (2)

Wayne Gulliver, Melinda J. Gooderham, Baojin Zhu, Christian Jossart, Sonia Montmayeur, Russel Burge & Catherine Reed. (2022) Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program. Dermatology and Therapy 13:1, pages 235-244.
Crossref
Rhea Singh, Esther A. Balogh & Steven R. Feldman. (2020) Update on IL-17 Inhibitors for Psoriasis. Current Dermatology Reports 9:4, pages 339-352.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.